Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy.

  title={Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy.},
  author={Aurelius Gabriel Omlin and Carmel Jo Pezaro and Silke Gillessen Sommer},
  journal={Therapeutic advances in urology},
  volume={6 1},
In the last three years, five novel treatments have been shown to improve survival in metastatic castration-resistant prostate cancer (CRPC). These novel treatments have distinct mechanisms of action: tubulin-binding chemotherapy (cabazitaxel); immunotherapy (sipuleucel-T); CYP-17 inhibition (abiraterone); androgen receptor (AR) blockade (enzalutamide); and radioisotope therapy (radium-223). For a number of years, docetaxel was the only treatment with a proven survival benefit for patients with… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 24 extracted citations


Publications referenced by this paper.
Showing 1-10 of 71 references

A randomized , multicenter , double - blind phase 3 trial comparing overall survival ( OS ) in patients ( pts ) with postdocetaxel castrationresistant

R. GerritsenW., D. KwonE., +3 authors C. Logothetis
prostate cancer ( CRPC ) and bone metastases treated with ipilimumab • 2013

Activity of cabazitaxel following docetaxel and abiraterone acetate in patients with castration-resistant prostate cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2013

Double - blind randomized trial of aflibercept versus placebo with docetaxel and prednisone for treatment of metastatic castrationresistant prostate cancer ( mCRPC )

I. Tannock, K. Fizazi, +3 authors I. Skoneczna
J Clin Oncol • 2013

Similar Papers

Loading similar papers…